Comparison of IPL Including Upper Lid or Lateral Canthus in Patients of MGD
The technology of treating meibomian gland dysfunction (MGD) with ophthalmic intense pulsed light (IPL) devices has been widely applied at home and abroad. Nevertheless, in clinical practice, whether to irradiate the upper eyelid varies considerably across devices of different brands due to technical discrepancies, resulting in substantial differences in operational protocols. Pre‑market clinical trials conducted by Meidixin Medical have verified that the five‑point irradiation protocol targeting the lower eyelid and lateral canthus features convenience, safety and efficacy. For this reason, this protocol has been vigorously promoted since the product launch. Nearly 10 years of real‑world clinical studies have further fully validated the safety and effectiveness of this therapeutic approach. A joint comparative study from South Korea and Japan divided MGD patients into three groups: the upper plus lower eyelid treatment group, the isolated lower eyelid treatment group, and the lower eyelid plus lateral canthus treatment group. The conclusion indicated that the therapeutic efficacy of the lower eyelid plus lateral canthus group was equivalent to that of the upper plus lower eyelid group, and both groups achieved superior outcomes compared with the isolated lower eyelid treatment group.

To determine the differences in the effects of intense pulsed light (IPL) treatment when including the upper and lower lid or lateral canthus area in patients with meibomian gland dysfunction (MGD).
Materials
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Severance Hospital (No. 4-2023-0539). A retrospective analysis was performed using medical records of patients diagnosed with MGD who underwent three IPL treatment sessions at 3-week intervals between March 2021 and November 2022.
Study Design
Patients were categorized into the following three groups based on the IPL treatment site: group A, patients who received IPL treatment only to the lower eyelid; group B,those who received IPL treatment to the lower and upper eyelids; and group C, those who received IPL treatment to the lower eyelids and lateral canthus area (Figure 1).

Figure 1
IPL Procedure
Intense pulsed light (IPL) therapy is administered first, followed by meibomian gland expression for drainage and unclogging.
Clinical Assessment
For all patients, ophthalmic examination results and OSDI scores were evaluated befor the first IPL treatment (3 weeks before IPL treatment) and after the third IPL treatment(3 weeks after IPL treatment).
(1)lipid layer thickness(LLT)
(2)corneal fluorescein staining(CFS)
(3)Tear break-up time test(TBUT)
(4)Lid margin abnormalities score(LAS)
(5)meibum expressibility(ME)
(6)Meibum quality(MQ)
(7)Type I Schirmer test(ST)
To ensure independent testing results, the ophthalmic examination was conducted in the following order:(1)LLT;(2)CFS;(3)TBUT;(4)LAS;(5)ME;(6)MQ;(7)ST.
1、IPL treatment significantly reduced CFS scores and significantly enhanced TBUT in all three groups. OSDI scores were significantly decreased in all groups after IPL treatment(Table 1).

2、Table 2 present the differences in ophthalmic examination results and OSDI scores in all three groups before and after IPL treatment. There was a significant difference in LAS between groups A and B and between groups A and C. However, no differences were observed between groups B and C. Except for LAS, no significant differences were observed between the three groups in terms of changes in ophthalmic examination results and OSDI scores before and after IPL treatment. During and after IPL treatments, no serious adverse effects were associated with the treatment options。

Numerous studies have demonstrated the remarkable efficacy of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD), which is undisputed. Nevertheless, considerable controversy surrounds the clinical operation of IPL. When IPL was first introduced for the clinical management of MGD‑related dry eye, only the lower eyelid was irradiated. To enhance therapeutic outcomes, researchers later proposed the protocol of irradiating both the upper and lower eyelids. However, IPL irradiation over the upper eyelid may induce prominent discomforts such as pain in patients, and the long‑term safety of upper‑eyelid irradiation remains to be evaluated.
The present study reveals that IPL irradiation of the lateral canthus yields therapeutic effects comparable to those of upper‑eyelid irradiation. This finding suggests that the lateral‑canthus region enables efficient thermal transmission and exerts significant neuromodulatory effects. Given the multiple drawbacks associated with upper‑eyelid treatment, the “lower‑eyelid plus lateral‑canthus” treatment protocol is of great clinical significance.
Link to the original article:https://www.mdpi.com/2077-0383/13/12/3581
In 2020, Tashbayev et al. from the University of Oslo, Norway, published a brief report recommending that the standard protocol for intense pulsed light (IPL) therapy of meibomian gland dysfunction (MGD) be the “lower eyelid plus lateral canthus” approach (Figure 2).

Figure 2
In 2022, Professor Yan Xiaoming et al. from Peking University First Hospital published a research paper confirming that when only the lower eyelid is irradiated with the EYESIS ophthalmic intense pulsed light therapeutic device, therapeutic effects can be observed in both the upper and lower eyelids. These findings are consistent with the clinical treatment outcomes of MGD patients.http://www.mdc-health.com/en/index.php?id=121

In the Chinese Clinical Guidelines for the Diagnosis and Treatment of Dry Eye Disease released in 2023, the recommended irradiation area for intense pulsed light therapy is also the lower eyelid plus lateral canthus region (Figure 3).

Figure 3
Furthermore, the important value of irradiating the lateral canthus also lies in its modulatory effect on the lacrimal gland. Researchers from the team of Professor Yan Xiaoming at Peking University First Hospital have found that intense pulsed light therapy can reverse the expression of lacrimal gland transcriptomic profiles, ameliorate mitochondrial structure and oxidative stress, and inhibit autophagy pathways. This in turn alleviates pathological damage and glandular atrophy of the lacrimal gland, which is of great value for the treatment of aqueous-deficient dry eye.

The evolution from the initial “lower‑eyelid‑only” protocol, through the “upper‑plus‑lower‑eyelid” approach, to the current “lower‑eyelid plus lateral‑canthus” regimen represents not merely a change in operational techniques, but also reflects that the indirect irradiation mechanism based on photobiomodulation (PBM) is gradually challenging the conventional direct irradiation mechanism. This trend suggests that the application value, modulatory mechanisms and standardized procedures of IPL may far exceed current understanding.
MDC EYESIS (MOPT)
10-pulse technology 5-point treatment
Easy to Operate · Safe and Effective
